Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir

NCT02931539 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

352

Enrollment

INDUSTRY

Sponsor class

Conditions

Cytomegalovirus (CMV)

Interventions

DRUG: Maribavir
DRUG: Ganciclovir
DRUG: Valganciclovir
DRUG: Foscarnet
DRUG: Cidofovir

Sponsor

Shire